Overview

* Forte Biosciences Q3 2025 net loss per share decreased compared to the same period in 2024

* Research and development expenses rose due to increased clinical trial activities

* Company expects three clinical trial readouts for FB102 in 2026

Outlook

* Forte expects three clinical trial readouts for FB102 in 2026

* Company anticipates topline data for celiac disease trial in 2026

* Forte sees 2026 as pivotal for FB102's market potential

Result Drivers

* CLINICAL TRIAL EXPANSION - Increased R&D expenses driven by expanded clinical trials for FB102 in celiac disease, vitiligo, and alopecia areata

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$17.68

Income mln

Q3 Basic -$0.99

EPS

Q3 -$18.38

Income mln

From

Operatio

ns

Q3 $18.38

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Forte Biosciences Inc ( FBRX ) is $57.50, about 75.9% above its November 13 closing price of $13.84

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)